» Articles » PMID: 34373602

Prevention of Vascular-allograft Rejection by Protecting the Endothelial Glycocalyx with Immunosuppressive Polymers

Abstract

Systemic immunosuppression for the mitigation of immune rejection after organ transplantation causes adverse side effects and constrains the long-term benefits of the transplanted graft. Here we show that protecting the endothelial glycocalyx in vascular allografts via the enzymatic ligation of immunosuppressive glycopolymers under cold-storage conditions attenuates the acute and chronic rejection of the grafts after transplantation in the absence of systemic immunosuppression. In syngeneic and allogeneic mice that received kidney transplants, the steric and immunosuppressive properties of the ligated polymers largely protected the transplanted grafts from ischaemic reperfusion injury, and from immune-cell adhesion and thereby immunocytotoxicity. Polymer-mediated shielding of the endothelial glycocalyx following organ procurement should be compatible with clinical procedures for transplant preservation and perfusion, and may reduce the damage and rejection of transplanted organs after surgery.

Citing Articles

Complement, Coagulation, and Fibrinolysis: The Role of the Endothelium and Its Glycocalyx Layer in Xenotransplantation.

Gultom M, Rieben R Transpl Int. 2024; 37:13473.

PMID: 39474588 PMC: 11518725. DOI: 10.3389/ti.2024.13473.


Mineralocorticoid receptor blockage in kidney transplantation: too much of a good thing or not?.

Afsar B, Afsar R, Caliskan Y, Lentine K Int Urol Nephrol. 2024; 57(3):839-854.

PMID: 39470940 DOI: 10.1007/s11255-024-04256-6.


The Endothelial Glycocalyx in Pig-to-Baboon Cardiac Xenotransplantation-First Insights.

Bender M, Abicht J, Reichart B, Leuschen M, Wall F, Radan J Biomedicines. 2024; 12(6.

PMID: 38927543 PMC: 11201800. DOI: 10.3390/biomedicines12061336.


Unlocking Transplant Tolerance with Biomaterials.

Pham J, Coronel M Adv Healthc Mater. 2024; 14(5):e2400965.

PMID: 38843866 PMC: 11834385. DOI: 10.1002/adhm.202400965.


A thicker skin for better immune evasion.

Schmidt E, Macauley M Nat Mater. 2024; 23(3):312-313.

PMID: 38438619 DOI: 10.1038/s41563-024-01822-2.


References
1.
Chambers D, Cherikh W, Goldfarb S, Hayes Jr D, Kucheryavaya A, Toll A . The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018; 37(10):1169-1183. DOI: 10.1016/j.healun.2018.07.020. View

2.
Moini M, Schilsky M, Tichy E . Review on immunosuppression in liver transplantation. World J Hepatol. 2015; 7(10):1355-68. PMC: 4450199. DOI: 10.4254/wjh.v7.i10.1355. View

3.
Shivaswamy V, Boerner B, Larsen J . Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. Endocr Rev. 2015; 37(1):37-61. PMC: 4740345. DOI: 10.1210/er.2015-1084. View

4.
Gutierrez-Dalmau A, Campistol J . Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007; 67(8):1167-98. DOI: 10.2165/00003495-200767080-00006. View

5.
Meier-Kriesche H, Li S, Gruessner R, Fung J, Bustami R, Barr M . Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006; 6(5 Pt 2):1111-31. DOI: 10.1111/j.1600-6143.2006.01270.x. View